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Abstract
Background: The Abelson helper integration-1 (AHI1) gene is required for both cerebellar and cortical development in
humans. While the accelerated evolution of AHI1 in the human lineage indicates a role in cognitive (dys)function, a linkage
scan in large pedigrees identified AHI1 as a positional candidate for schizophrenia. To further investigate the contribution of
AHI1 to the susceptibility of schizophrenia, we evaluated the effect of AHI1 variation on the vulnerability to psychosis in two
samples from Spain and Germany.
Methodology/Principal Findings: 29 single-nucleotide polymorphisms (SNPs) located in a genomic region including the
AHI1 gene were genotyped in two samples from Spain (280 patients with psychotic disorders; 348 controls) and Germany
(247 patients with schizophrenic disorders; 360 controls). Allelic, genotypic and haplotype frequencies were compared
between cases and controls in both samples separately, as well as in the combined sample. The effect of genotype on
several psychopathological measures (BPRS, KGV, PANSS) assessed in a Spanish subsample was also evaluated. We found
several significant associations in the Spanish sample. Particularly, rs7750586 and rs911507, both located upstream of the
AHI1 coding region, were found to be associated with schizophrenia in the analysis of genotypic (p = 0.0033, and 0.031,
respectively) and allelic frequencies (p = 0.001 in both cases). Moreover, several other risk and protective haplotypes were
detected (0.006,p,0.036). Joint analysis also supported the association of rs7750586 and rs911507 with the risk for
schizophrenia. The analysis of clinical measures also revealed an effect on symptom severity (minimum P value = 0.0037).
Conclusions/Significance: Our data support, in agreement with previous reports, an effect of AHI1 variation on the
susceptibility to schizophrenia in central and southern European populations.
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Introduction
Because of its early onset, severity and chronic course
schizophrenia is one of the most devastating neuropsychiatric
disorders and represents a major public health concern [1].
Although the pathogenetic mechanisms leading to this disorder are
largely unclear, it is well accepted that schizophrenia is the result
of a complex interplay between genetic variants and environmen-
tal factors of different nature [2–4]. Until now, the search for
susceptibility genes has given promising results, although some
inconsistencies have also arisen [5–7]. Interestingly, several linkage
studies have located putative schizophrenia as well as bipolar
disorder susceptibility loci on the long arm of chromosome 6, and
particularly in the 6q15–23.2 region [8]. Different genome-wide
association studies (GWAS) also support association between
Single Nucleotide Polymorphisms (SNPs) located in 6q21–6q25
and psychotic disorders [9–12]. In agreement with these findings,
an autosomal scan of Arab-Israeli families [13,14] supported
linkage to schizophrenia to 6q23. This linkage peak contains a
neurodevelopmental gene, the Abelson helper integration site 1
gene (AHI1). This gene is required for both cerebellar and cortical
development in humans and several null-type and missense
mutations in AHI1 have been shown to cause Joubert syndrome,
a rare autosomal recessive neurodevelopmental disorder, charac-
terized by cognitive and behavioural disturbances among other
clinical symptoms [15,16].
The human AHI1 gene contains 31 exons and generates at least
three alternative isoforms. AHI1 protein, also known as Jouberin
[16], contains seven Trp-Asp (WD) repeats, a Src homology 3
(SH3) domain and a coiled-coil domain. Jouberin is conserved in
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different mammalian species, particularly in the WD40 and SH3
domains [15]. The presence of both WD40 and SH3 domains in
signaling and adaptor molecules suggests that AHI1 may play an
important role in signal transduction in normal cells, as an adaptor
protein recruiting other signaling molecules and modulating and
integrating their action [16,17]. However, little is known about
how AHI1 is involved in the development of the central nervous
system (CNS). AHI1 mRNA is highly expressed in both the
developing and the mature brain [15,16]. Interestingly, it has been
found [18] that murine Ahi1 protein forms a stable complex with
huntingtin-associated protein 1 (Hap1). This complex appears to
be critical for neonatal development through its function in
intracellular trafficking, neurogenesis and neuronal differentiation.
Taken together, AHI1 is an attractive candidate for a
schizophrenia susceptibility gene and three association studies
have been performed with promising results. In the first study in
an inbred Arab-Israeli family sample and in an outbred nuclear
family sample, Amann-Zalcenstein et al. [19] were able to identify
seven markers strongly associated with schizophrenia. The
association was found in a 500 kb linkage disequilibrium (LD)
block on chromosome 6 harbouring AHI1. Subsequently, this
association has been replicated in an independent European
cohort from Iceland [20], in another large European sample [21],
as well as in an enlarged sample from the original study [22]. In
the latter, the significant SNPs were localized in a substructure of
the large original LD block, which contains AHI1 and the C6orf217
gene, and may contain regulatory elements for both the AHI1 and
the neighboring phosphodiesterase 7B gene (PDE7B). Further-
more, there is also evidence of an association between an AHI1
haplotype and autistic disorder (ASD) in a region of the gene that
had been previously associated with schizophrenia [23].
Here we report the results from a case-control association study
performed on two different samples from Germany and Spain.
Our main aim was to test the hypothesis that AHI1 variants were
associated with schizophrenia as well as dimensional measures of
disease severity.
Results
Spanish sample
SNP18 (rs4896156) deviated from Hardy-Weinberg Equilibri-
um (HWE) in the control sample (P= 3.89.1026), clearly
suggesting a low genotyping quality for this polymorphism. For
this reason, this SNP was discarded.
Figure 1a shows the pairwise linkage disequilibrium values
observed in the control sample. The LD pattern from the
schizophrenic sample (information not shown) was very similar.
r2 values ranged between 0.0 and 0.993. According to Gabriel et al.
[24] criteria, five LD blocks were detected. SNPs 1, 2, 3, 13 and 17
presented the lowest LD values (both r2 and D’) when compared
with the rest of the SNPs.
Single SNP association analysis revealed that SNP14
(rs7750586) was associated with psychosis, since both the G allele
and the G/G genotype were more frequent in the group of
patients with schizophrenia (P = 0.001 for the genotypic compar-
isons (recessive model); see table 1 for the allelic comparisons). The
G allele of SNP27 (rs911507) also was associated with schizo-
phrenia (table 1) and the same result was observed in the analysis
of genotypic frequencies (P = 0.001, recessive model). Nevertheless,
the significant values did not withstand the correction for multiple
testing in the analysis of the allelic frequencies, although the P
value corresponding to the analysis of genotypic frequencies still
remained significant (P = 0.02 for both SNPs). We also performed
a haplotype analysis, as well as an analysis of two-, three- and four
marker haplotype sliding windows. As a result, several significant
risk and protective haplotypes were detected (see table 1). The
haplotypes encompassed SNPs 1, 2, 3 and 4 (located in the 39
region of the analyzed genomic area), as well as markers 13, 14, 15
and 16 (located in intron 2 and in the 59 putative regulatory region
of AHI1 gene). Interestingly, 5 of these significant haplotypes
remained significant after a 1000-permutation run.
We next studied whether any of the SNPs associated to risk for
psychosis in the single-SNP and haplotype analysis (SNP1, SNP2,
SNP3, SNP4, SNP13, SNP14, SNP15, SNP16, and SNP27) had
any impact on several clinical scores, namely Brief Psychiatric
Rating Scale (BPRS), Psychiatric Assessment scale or KGV
Symptom scale, and finally the total, general, positive and negative
scores from the Positive and Negative Syndrome scale (PANSS).
Significant results are displayed in table 2 with SNP4, SNP14 and
SNP15 appearing to modulate the severity of psychotic symptoms,
evaluated through PANSS, BPRS and KGV scales.
German sample
The genotyping for SNP7 and SNP19 did not pass the quality
control in the sample of healthy subjects and were omitted from
further analysis. LD structure for the control sample can be seen in
figure 1b. These values were very similar for the affected subjects
(data not shown) and ranged between 0.0 and 0.87. 6 blocks
according to Gabriel et al. [24] criteria were detected. By contrast,
the 39 region of the AHI1 gene (SNP1 to SNP3) featured lower
pairwise LD values.
Regarding the single SNP association analysis (table 1), none of
the 29 AHI1 SNPs selected for the study differed in their allelic and
genotypic frequencies between schizophrenic patients and controls
(P,0.01). The haplotype analysis also yielded negative results.
Combined sample
The German and the Spanish samples were combined to
perform a heterogeneity test and an association analysis of the
genotypic frequencies (Table 1) through Cochran-Mantel-Haens-
zel (CMH) tests, as well as a haplotype analysis through a
retrospective likelihood algorithm combined with a x2 test.
Heterogeneity tests revealed a significantly different genotype
distribution of SNPs 1, 11, 12, 17, 22 and 27 in both the Spanish
and the German sample (data not shown). Overall, we detected
differences between patients and controls for two SNPs (SNP14
and SNP27), which were most likely due to a specific association in
the Spanish sample.
Discussion
Here we present the results for a case-control association
analysis that explores the impact of variation at AHI1 locus on the
vulnerability towards schizophrenia in two European samples of
Caucasian origin from Southern Germany and East Spain. For
this analysis, we focused on 29 tag SNPs located in the region
corresponding to the linkage peak detected by Amann-Zalcenstein
et al. [19]. Among these SNPs, we included those 7 SNPs which
have been widely studied and associated with schizophrenia in
different populations [19–21]. Several alleles and haplotypes were
significantly associated with the risk for schizophrenia in the
Spanish and, less pronounced, the combined sample. Some
protective haplotypes were also found.
There are several reasons to consider AHI1 a candidate gene for
psychotic disorders. First, AHI1 expression has been detected in
brain areas particularly related to the pathophysiology of psychotic
symptoms, including hippocampus, cerebral cortex, mesolimbic
pathways, cerebellum, inferior colliculus and dorsal cochlear
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nucleus [15,25–30]. Another interesting issue is the accelerated
evolution, probably due to positive selection, of AHI1 along the
primate lineage leading to humans [15,31]. Given that AHI1 is
critical for a proper neurodevelopment, accelerated evolution of
AHI1 in the human lineage may indicate the effect of directional
selection. These observations suggest the involvement of this gene
in the acquisition of higher cognitive and mental abilities in
humans, a phenomenon which can be linked to the appearance of
mental disorders such as schizophrenia [32–34]. Remarkably, it is
not uncommon that genes causing monogenic rare diseases can
also contribute to common complex diseases [35,36]. Therefore, it
cannot be excluded that more subtle variation in AHI1 than those
causing Joubert syndrome may have a role in the vulnerability to
neuropsychiatric disorders.
While the study presented here was designed and performed,
three case-control association studies reported the involvement of
AHI1 in the susceptibility to schizophrenia [19,20] and autistic
disorder [23]. According to these antecedents, we performed the
present study, which intends to extend the study of AHI1 gene to
other populations in an attempt to find schizophrenia-associating
markers in the Caucasian European context.
In summary, support for a role of AHI1 in psychotic disorder
was obtained in the sample from Valencia (East Spain), in which
two SNPs located upstream from AHI1 gene (SNP14-rs7750586
and SNP27-rs911507) were significantly associated with schizo-
phrenia, with a moderate effect size (Odds Ratios (ORs) were 1.53
and 1.34, respectively). However, with regard to rs7750586, the
risk allele associated with schizophrenia in our study (G allele) was
different than in the two previous studies [19–20]. Moreover, we
also found protective as well as risk haplotypes spanning SNP1 to
SNP4, and SNP13 to SNP16, i.e. including the associated risk
marker. This marker also impacted dimensional severity scores of
Figure 1. Linkage disequilibrium (LD) pattern of AHI1 gene. Figures represent pairwise r2 values observed in control subjects from German (a)
and Spanish (b) origin. Values are represented in a grayscale ranging from white (no LD) to black (high LD).
doi:10.1371/journal.pone.0012254.g001
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Table 1. Single alleles and haplotypes of the AHI1 region associated with schizophrenia in the present study.
GERMAN SAMPLE (N = 247
patients+360 controls)
SPANISH SAMPLE (N = 280 patients+348
controls)
COMBINED SAMPLE (N = 558 patients+708
controls)
Single SNP or
haplotypea
Cont
freq
SCZ
freq OR (95% CI) P
Cont
freq
SCZ
freq OR (95% CI) P
Cont
freq
SCZ
freq OR (95% CI) P
SNP14
(rs7750586)
0.353
(G)
0.323
(G)
0.88 (0.67–1.14) 0.315 0.286
(G)
0.380
(G)
1.53 (1.15–2.04) 0.003 (0.086) 0.325 0.360 1.52 (1.13–2.06) 0.006
SNP27
(rs911507)
0.342
(G)
0.356
(G)
1.07 (0.82–1.39) 0.619 0.370 0.441 1.34 (1.03–1.76) 0.031 (0.81) 0.331 0.386 1.34 (1.02–1.77) 0.038b
SNP1-SNP4
(TAGG)
0.108 0.081 0.43 (0.031–5.87) 0.277 0.0868 0.025 0.69 (0.19–3.91) 0.006
(global:0.004)
0.099 0.055 0.71 (0.19–2.54) 0.011
(global:0.126)
SNP1- SNP4
(TATA)
0.222 0.223 0.57 (0.04–7.43) 0.853 0.212 0.305 3.41 (0.73–16) 0.007 (ns after
perm. run)
(global:0.004)
0.217 0.264 1.55 (0.45–5.29) 0.027
(global:0.126)
SNP13-SNP15
(TAA)
0.588 0.600 0.85 (0.51–1.44) 0.663 0.628 0.555 0.91 (0.51–1.61) 0.036
(global:0.044)
0.603 0.578 0.89 (0.59–1.31) 0.324
(global:0.458)
SNP13-SNP15
(TGC)
0.348 0.328 0.79 (0.46–1.35) 0.469 0.293 0.380 1.33 (0.74–2.41) 0.009
(global:0.044)
0.325 0.353 1.00 (0.67–1.49) 0.255
(global:0.458)
SNP14-SNP16
(AAA)
0.572 0.588 1 (reference) 0.613 0.609 0.529 1 (ref) 0.025 (ns after
perm. run)
(global:0.046)
0.587 0.560 1 (ref) 0.276
(global:0.489)
SNP14-SNP16
(GCG)
0.345 0.328 0.92 (0.70–1.22) 0.584 0.288 0.369 1.48 (1.08–2.00) 0.014
(global:0.046)
0.321 0.348 1.13 (0.92–1.39) 0.237
(global:0.489)
Significant values are marked in bold. The corrected P-values are indicated in brackets.
aTo avoid redundant information, other significant haplotypes, which are variations of other larger significant haplotypes from this table, have not been included.
bSNP27 had significantly different genotypic distributions in the German and the Spanish sample (heterogeneity P value = 0.016 uncorrected).
Abbreviations: Cont, control; SCZ, schizophrenia; ns, not significant; perm, permutation; ref, reference haplotype.
doi:10.1371/journal.pone.0012254.t001
Table 2. AHI1 SNPs significantly associated with clinical traits in the Spanish sample.
SNP Genotypic distribution Average response (SE) Difference (95% CI) Model Pa
PANSS total score
SNP4 (rs6931735) A/A–G/A = 61 61.98 (2.06) 0.00 Recessive 0.05 (0.3)
G/G = 19 70.68 (4.27) 8.70 (0.12–17.29)
SNP14 (rs7750586) A/A–A/G = 59 60.25 (1.66) 0.00 Recessive 0.017 (0.136)
G/G = 18 70.06 (4.85) 9.80 (1.94–17.66)
SNP15 (rs9647635) A/A–C/A = 60 63.58 (2.09) 0.00 Recessive 0.023 (0.161)
C/C = 13 75.62 (5.63) 12.03 (1.86–22.20)
PANSS General Score
SNP4 (rs6931735) A/A–G/A = 61 31.54 (1.05) 0.00 Recessive 0.042 (0.252)
G/G = 19 36.26 (2.37) 4.72 (0.23–9.21)
SNP14 (rs7750586) A/A–A/G = 59 30.78 (0.84) 0.00 Recessive 0.016 (0.112)
G/G = 18 36.17 (2.86) 5.39 (1.11–9.66)
SNP15 (rs9647635) A/A–C/A = 60 32.28 (1.02) 0.00 Recessive 0.0037 (0.029)
C/C = 13 40.23 (3.25) 7.95 (2.76–13.13)
BPRS
SNP14 (rs7750586) A/A–A/G = 59 44.8 (1.22) 0.00 Recessive 0.045 (0.315)
G/G = 19 50.5 (3.15) 5.70 (0.21–11.19)
KGV scale
SNP15 (rs9647635) A/A–C/A = 157 9.35 (0.41) 0.00 Recessive 0.049 (0.392)
C/C = 30 11.43 (1.05) 2.08 (0.02–4.14)
Significant P values (P,0.05) are indicated in bold.
aThe corrected P value is indicated in brackets.
Abbreviations: SE, standard error; CI, confidence interval.
doi:10.1371/journal.pone.0012254.t002
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schizophrenia, lending further support to the categorical case-
control finding. Remarkably, many of the significant SNPs are
located in putative regulatory regions. The significant haplotypes
including SNP1 to SNP4 are of special interest because they span a
region encoding the SH3 domain, one of the most important
regions of Jouberin and particularly conserved in mammals
[15,16].
With regard to the negative results in the German sample, it
should be noted that this sample was enriched for chronic, non-
remitting schizophrenia, so that one might hypothesize that AHI1
is associated with less severe, remitting forms of this disorder, a
hypothesis which could easily be tested in further studies. In
addition, we may also consider that the existence of differences in
the clinical phenotyping of patients (DSM-IV criteria were used in
the Spanish sample, whereas ICD-10 was the reference in the
German dataset) may explain the differences observed between
both samples in the case-control association analysis.
Interestingly, we also found some SNPs associating with
schizophrenia in the combined German-Spanish sample. The
higher size of this sample is of special interest because it increases
the statistical power to detect association with the risk for
schizophrenia (table 2). Indeed, sample size is one of the most
important issues in the study of the genetics of complex diseases.
However, the significant association observed in the joint dataset
reduced significance of the results from the Spanish sample,
therefore suggesting that the positive finding in the combined
sample is mainly due to the SNP distribution in the Spanish
sample. The differences among samples observed in the
heterogeneity tests for some SNPs can also make it difficult to
perform and interpret a study with a joint group of individuals
from different origin. Indeed, it cannot be discarded that the
differences observed between the Spanish and the German sample
could be related to differences in the genetic structure of both
populations. Although European populations share an important
part of their genetic structure, they also present clear differences
which should be taken into account when a case-control
association analysis is designed [37–39]. These differences in the
genetic structure of Spanish and German populations can involve
other genetic interacting factors, which, in turn, may modulate the
effect of the polymorphism of interest on the vulnerability to a
complex disease. In addition, the differences in the directionality of
the findings between the Spanish sample and previous reports also
point to different issues. One paradigmatic example of this
situation is the dysbindin gene, where every one of its five major
haplotypes has been associated with schizophrenia [40]. This fact
can be related, on one hand, to differences among populations
and, on the other hand, to different study designs. In our study, to
avoid an effect due to population stratification [41,42], affected
and control subjects were carefully matched on ethnicity, gender
and age, and for the German sample the absence of population
substructure has already been shown [43]. Finally, as it has been
previously commented, we cannot discard that differences in the
LD pattern may mask the existence of common causal variants
among populations.
Finally, as a complement to our case-control association study,
we evaluated the impact on several clinical variables (PANSS,
BPRS and KGV scales) of those AHI1 SNPs associated with
schizophrenia in this study. Although we found a slight effect of
AHI1 gene on symptom severity, additional studies on more
specific variables (particularly of cognitive nature) and with more
individuals would be necessary to confirm this finding.
In conclusion, the findings from the present study lend support
to the notion that the AHI1 locus increases the genetic risk for
psychoses at least in some populations. However, additional
analyses with larger samples are necessary. Indeed, while this
manuscript was in preparation, two additional analyses were
published, one of them including a large number of different
European samples [21], as well as another study that focused on a
dense SNP map of the AHI1 region [22]. Both studies also
supported the hypothesis that AHI1 is involved in the pathogenesis
of schizophrenia. Therefore, our study, together with previous
studies in different Caucasian populations, supports the relation-
ship between genetic variation in AHI1 and the risk for
schizophrenia.
Materials and Methods
Ethics Statement
All subjects gave their written informed consent to participate in
this study, which was approved by the Ethical Committees of the
Medical Faculty, University of Valencia and the University of
Wu¨rzburg.
Clinical samples
The Spanish sample consisted of 280 unrelated psychotic
patients and 348 control subjects. Patients came from the
psychiatric in-patient and out-patient units of the Mental Health
Service 4 of the Clinical Hospital, University of Valencia, Spain.
Age ranged from 18 to 77 years. The retrospective clinical data
collected from each patient were compared with the information
provided from previous clinical reports and family members. All
patients met DSM-IV criteria for different psychoses, mainly
schizophrenia (76%). These diagnoses were confirmed for every
patient by a consensus meeting with the treating psychiatrist and
one of the psychiatrists of our research group. Patients also had a
minimum one-year evolution of the illness and were on
antipsychotic treatment at evaluation time. Exclusion criteria for
this study included incoherence of speech and/or the incapacity
for basic comprehension of the questions. Symptom severity was
assessed in some patients through BPRS, KGV and PANSS scales
(80, 200 and 80 individuals, respectively). The 348 healthy
unrelated subjects had no history or familial background of
psychiatric disorders. To avoid sample stratification, these subjects
had similar demographic characteristics (Caucasian ethnic group,
similar age) to the psychotic group. They were between 18 and 91
years old and were also of Spanish origin. Drug abuse was also
considered among the exclusion criteria.
The German sample was enrolled at the Department of
Psychiatry, Psychosomatics and Psychotherapy, University of
Wu¨rzburg. A total of 247 unrelated patients meeting ICD-10
criteria for schizophrenia (mean age, 42 years) took part in the
study. They were at least once in-patients at the Department of
Psychiatry and none of the patients remitted completely during the
course of disease, i.e. the sample was enriched for chronic and
severe schizophrenia. Diagnoses were made by an extensive, semi
structured interview performed by an experienced psychiatrist.
Clinical data obtained from the interview was contrasted with the
information obtained from family members and previous clinical
assessments. Symptom severity was assessed in some individuals
through BPRS. Patients did not show other disorders (neurological
disorders, epilepsy, mental retardation) which could be the
underlying cause of the psychiatric disorder. Substance-induced
psychosis and affective disorders were also considered as exclusion
criteria. A total of 360 control subjects were also included in the
study. They were healthy blood donors from the same catchment
area as the patient group (Lower Franconia, Bavaria). To avoid
ethnic stratification, they were also from Caucasian origin.
Although these individuals were not assessed for psychiatric
AHI1 Gene and Schizophrenia
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disorders, all of them were free of medication and the aim of the
study was explained to them, so it is unlikely that the subjects from
the control group are suffering from severe psychiatric disorders.
Only those patients and controls who gave their written informed
consent were accepted for the study.
Genotyping
Genomic DNA was isolated from the peripheral blood of
patients and controls according to standard procedures. Thirty
single-nucleotide polymorphisms (SNPs) were initially selected
from previous studies. However, one of them (rs6935033) was
discarded during the design of the genotyping assay. Finally,
twenty-nine SNPs were included in the study (see table 3 and
figure 2 for more information about the markers). These SNPs
covered the entire AHI1 genomic region, as well as a 25 kb region
located 59 of AHI1. Upstream SNPs of AHI1 were analyzed
because the highest association signals from the original study from
Amann-Zalcenstein et al. [19] were located in this region. SNP
genotyping was performed in both samples through the iPLEX
assay on the MassARRAY platform (Sequenom, San Diego, CA,
USA), which allows high throughput genotyping through
multiplex reactions. Exclusion criteria during quality control of
the genotyping procedure were the following: HWE P-value below
0.05 in the control sample, genotyping rate below 70% and minor
Figure 2. Genomic region and SNPs analyzed in this study. The position of each SNP is indicated with an orange arrow.
doi:10.1371/journal.pone.0012254.g002
Table 3. List of SNPs included in the present study.
rs code (or
other name)
Position (dbSNP
Build 127)
Marker
order
Distance
from SNP1
Allele
change CEU MAF
Location/
Function
rs2327587 135622646 SNP1 0 C/T 0.408 (A) 39 near gene
rs9494193 135625316 SNP2 2670 A/C 0.433 (C) 39 near gene
rs4896142 135664512 SNP3 41866 G/T 0.383 (G) Intron 25
rs6931735 135666504 SNP4 43858 A/G 0.408 (G) Intron 25
rs6912933 135669227 SNP5 46581 A/G 0.425 (G) Intron 25
rs9321501 135683110 SNP6 60464 A/C 0.397 (C) Intron 24
rs2746429 135714977 SNP7 92331 C/T 0.395 (C) Intron 23
rs2614258 135718895 SNP8 96249 A/G 0.350 (A) Intron 23
rs2246943 135733209 SNP9 110563 A/T 0.400 (A) Intron 22
rs2614264 135752387 SNP10 129741 A/G 0.400 (G) Intron 22
rs11154801 135781048 SNP11 158402 A/C 0.317 (A) Intron 19
rs2757643 135802926 SNP12 180280 A/C 0.381 (A) Intron 13
rs6928455 135859828 SNP13 237182 C/T 0.051 (C) Intron 2
rs7750586 135869366 SNP14 246720 A/G 0.325 (G) 59 near gene
rs9647635 135882749 SNP15 260103 A/C 0.322 (C) 59 near gene
rs12203875 135902107 SNP16 279461 A/G 0.383 (G) 59 near gene
rs10484771 135939628 SNP17 316982 C/T 0.058 (T) 59 near gene
rs4896156 135968556 SNP18 345910 A/G 0.322 (G) 59 near gene
rs9376112 135969693 SNP19 347047 A/C 0.308 (C) 59 near gene
rs2143681 135974698 SNP20 352052 A/G 0.314 (A) 59 near gene
rs6925684 135978571 SNP21 355925 A/G 0.312 (A) 59 near gene
rs6902485 135999485 SNP22 376839 A/G 0.042 (G) 59 near gene
rs7739635 136039471 SNP23 416825 C/T 0.322 (T) 59 near gene
rs9494332 136050301 SNP24 427655 A/G 0.280 (G) 59 near gene
rs2273069 136052491 SNP25 429845 A/G 0.310 (G) in Asians 59 near gene
rs1475069 136097927 SNP26 475281 A/C 0.283 (C) 59 near gene
rs911507 136101116 SNP27 478470 A/G 0.230 (G) 59 near gene
rs12211505 136116514 SNP28 493868 C/T 0.250 (C) 59 near gene
rs2208574 136117310 SNP29 494664 A/G 0.258 (A) 59 near gene
Abbreviations: CEU, CEPH collection - DNA samples of Utah residents with ancestry from northern and western Europe; MAF, minor allele frequency.
doi:10.1371/journal.pone.0012254.t003
AHI1 Gene and Schizophrenia
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12254
allele frequency (MAF) below 0.04. According to these criteria,
one SNP (SNP18) was discarded in the Spanish sample (HWE P-
value = 0.0389 in the control sample, genotyping rate 53,1%), as
well as two SNPs (SNP7 and SNP19) were discarded in the
German sample (genotyping rate 0% in the control sample).
Moreover, in the Spanish sample, 25 controls and 37 patients were
discarded due to the low genotyping rate, while two controls and
three patients were discarded in the German sample. The high
number of discarded samples in the Spanish dataset may be
due to the DNA extraction procedures, given that a subset of
Spanish DNA samples was extracted by the phenol-chloroform
methodology.
Statistical analysis
Prior to any association analysis, it is important to make a priori
calculation to know the statistical power of the study. This power
varies attending to different parameters, such as the sample size,
the risk allele frequency, the incidence of the disease and the risk
(odds ratio) assumed for each polymorphism, among others. For
this study, QUANTO software version 1.2.3 was used to calculate
the statistical power to find associations between genetic
polymorphisms and the risk for schizophrenia. We assumed an
odds ratio (OR) between 1.3 and 2. We also set the incidence of
schizophrenia at 1% and the inheritance model as additive. The
estimations for our different samples are summarized in table 4.
Particularly, this power ranged between 0.149 and 0.999
depending on the sample size, the risk associated to each allele
and the allele frequencies. Thus, for those polymorphisms with a
low MAF, the statistical power to detect association with the
disease is expected to be lower, especially if the risk is low. In our
particular case, 21 of the 29 SNPs presented a MAF equal to or
higher that 0.3, and only 3 SNPs had a MAF lower than 0.1.
Therefore, we consider the statistical power of the study to be
adequate.
Genotypes were assessed for Hardy-Weinberg Equilibrium
(HWE) in both patient and control samples by applying a x2 test
implemented with Haploview Program version 4 [44]. As the
deviation from HWE in the control sample could be indicating a
genotyping error, those SNPs which deviated from HWE in the
control sample (P,0.1) were discarded from the analysis.
Differences in the allelic frequencies between patients and
controls were evaluated with a x2 test via Unphased program
Table 4. Estimation of the statistical power associated to the different case-control and family-based studies.
Type of study Sample N
Frequency of
the risk allelea
Statistical
Power
OR = 1.3 OR = 1.6 OR = 1.9
Case-control Spanish 243 patients 0.04 0.149 0.307 0.678
323 controls 0.09 0.261 0.554 0.933
0.14 0.355 0.709 0.984
0.19 0.429 0.801 0.995
0.24 0.487 0.855 0.998
0.29 0.529 0.887 0.999
0.34 0.558 0.906 0.999
0.39 0.577 0.916 0.999
0.44 0.586 0.919 0.999
Case-control German 243 patients 0.04 0.153 0.318 0.698
358 controls 0.09 0.271 0.573 0.943
0.14 0.368 0.728 0.987
0.19 0.445 0.818 0.997
0.24 0.503 0.870 0.999
0.29 0.546 0.899 0.999
0.34 0.576 0.917 0.999
0.39 0.594 0.926 0.999
0.44 0.603 0.929 0.999
Case-control Combined 486 patients 0.04 0.252 0.540 0.930
681 controls 0.09 0.464 0.843 0.978
0.14 0.613 0.945 0.989
0.19 0.713 0.978 0.999
0.24 0.779 0.989 0.999
0.29 0.821 0.994 0.999
0.34 0.847 0.996 0.999
0.39 0.862 0.997 0.999
0.44 0.869 0.997 0.999
aThe risk allele was considered to be the minor allele.
Abbreviation: OR, Odds Ratio.
doi:10.1371/journal.pone.0012254.t004
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version 3.0.12 [45,46]. Moreover, the web-based application
SNPStats [47] was used to compare, by means of logistic
regression, the genotypic frequencies between groups. Different
inheritance models (codominant, dominant, recessive, and addi-
tive) were tested. ORs and 95% confidence intervals as indicators
of the risk associated to each genotype were also calculated.
Finally, if any SNP was found to be associated with the risk for
schizophrenia, a linear regression analysis with SNPstats was used
to evaluate the effect of those SNPs on several clinical scores
(BPRS, PANSS and KGV). Bonferroni sequential test for multiple
comparisons [48] was applied to correct all the reported p-values.
Regarding the haplotype analysis, haploblock frequencies were
compared between patients and controls with Haploview Program
version 4 [44]. Moreover, frequencies of sliding windows of two,
three and four-marker haplotypes were estimated through a
retrospective likelihood algorithm and compared between patients
and controls with the Unphased software version 3.0.12 [45,46]. It
should be noted that haplotypes with a frequency below 0.03 were
considered as rare and therefore discarded from the statistical
analysis. A 1000-permutation run was performed in all haplotype
analyses to better estimate the significance of the positive
associations.
We also performed a joint analysis by combining the affected
individuals and healthy subjects from Spain and Germany. The
linkage disequilibrium patterns between SNPs were determined to
assess the validity of such type of analysis. Moreover, these
analyses were only stratified according to the region of origin of
each individual (Germany or Spain) since there were no
differences in other possible stratification variables, for example
ethnicity. PLINK software version 1.0.2 [49] was used to apply
two different CMH tests, which are based on an ‘‘average’’ OR
that controls for the potential confounding due to the cluster
variable. Two variants of the CMH tests were performed: a) a
CMH test that performs the case-control association test but
controlling the effect of the cluster variable (in our particular case,
the cluster variable was the country of origin); b) a CMH test that
is used as a measure of the heterogeneity between samples, which
assesses whether a particular SNP varies between clusters. Finally,
we also performed a haplotype analysis following the same
procedures described above for the Spanish and the German
sample separately.
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